Thus, these results highlight a tolerable and promising anti-tumor activity in ICI-refractory melanoma when combining CD1c (BDCA-1)+ +/− CD141 (BDCA-3)+ myDCs with T-VEC. This evidence concerns the gene CD1C and melanoma.